Brief review: Chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions

Chronic cancer pain is a serious complication of malignancy or its treatment. Currently, no comprehensive, universally accepted cancer pain classification system exists. Clarity in classification of common cancer pain syndromes would improve clinical assessment and management. Moreover, an evidence-based taxonomy would enhance cancer pain research efforts by providing consistent diagnostic criteria, ensuring comparability across clinical trials. As part of a collaborative effort between the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) and the American Pain Society (APS), the ACTTION-APS Pain Taxonomy initiative worked to develop the characteristics of an optimal diagnostic system. After the establishment of these characteristics, a working group consisting of clinicians and clinical and basic scientists with expertise in cancer and cancer-related pain was convened to generate core diagnostic criteria for an illustrative sample of 3 chronic pain syndromes associated with cancer (ie, bone pain and pancreatic cancer pain as models of pain related to a tumor) or its treatment (ie, chemotherapy-induced peripheral neuropathy). A systematic review and synthesis was conducted to provide evidence for the dimensions that comprise this cancer pain taxonomy. Future efforts will subject these diagnostic categories and criteria to systematic empirical evaluation of their feasibility, reliability, and validity and extension to other cancer-related pain syndromes.

show abstract

“…In the most severe cases sensory and motor alterations are disabling, resulting in paralysis, complete loss of function, or both. 101,104,147 …”

Section: Resultsmentioning

confidence: 99%

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

Paice¹,

Mulvey

Bennett

et al. 2017

The Journal of Pain

View full text Add to dashboard Cite

show abstract

“…As early detection of it is a means to prevent persistent CIPN (Massey, Kim, & Abdi, 2014), it is important to encourage patients to report CIPN as soon as possible and monitor it closely (Banach et al, 2016). However, patients find it difficult to express how they experience CIPN as the symptoms are multifaceted and to some degree blurry (Miltenburg & Boogerd, 2014;Tanay, Armes, & Ream, 2017).…”

Section: Backg Rou N Dmentioning

confidence: 99%

Involving patients and nurses in choosing between two validated questionnaires to identify chemotherapy‐induced peripheral neuropathy before implementing in clinical practice—A qualitative study

Jensen

Yilmaz

Pedersen

2020

Journal of Clinical Nursing

View full text Add to dashboard Cite

Aims and objectives To explore from a nurse and patient perspective what questionnaire—“Functional assessment of cancer treatment gynecological group neurotoxicity” or “Oxaliplatin‐Associated Neuropathy Questionnaire”—best describes chemotherapy‐induced peripheral neuropathy and its influence on everyday life in a comprehensive and meaningful way, prior to implementation in daily practice. Background Patients experience chemotherapy‐induced peripheral neuropathy during and after chemotherapy for colorectal cancer with oxaliplatin. This neuropathy is difficult to describe for patients and to identify for nurses. To address the specific needs of patients and improve identification of neuropathy and its influence on everyday life, we wanted to implement a questionnaire in clinical practice. Design A phenomenological hermeneutic frame of reference was used. Method Semi‐structured interviews with 15 patients and two focus groups with eight cancer nurses were used for data collection. Data were organised and interpreted by content analytical steps in a hermeneutical process. COREQ checklist was used in reporting of the study. Results The analysis resulted in two main themes (a) “To dig deeper” with sub‐themes “to identify the line between acceptable and nonacceptable chemotherapy‐induced peripheral neuropathy,” and “searching for a precise description.” (b). “When everything is interrelated” with sub‐themes “to be aware of different perspectives and understandings” and “recognise potential pitfalls.” Conclusion Involving patients and nurses in choosing between the two questionnaires revealed that neither alone was sufficient to describe the patients’ experiences. Instead, it seems essential to implement both questionnaires, using the answers as a basis for a dialogue to address the patients’ specific needs. Relevance for clinical practice Using patients and nurses perspectives in a complementary way may provide a solid foundation before starting an implementation process in clinical practice. However, attention must be paid to potential barriers and facilitators as well as the fact that a successful implementing process requires leadership and information sharing.

show abstract

“…Mitochondrial damage also increases permeability to and release of intracellular calcium, which causes activation of protein kinase C, phosphorylation of transient receptor potential vanilloid (TRPV), activation of capases and calpains, and the release of nitric oxide and free radicals. The end result is cytotoxic to axons and neuronal cell bodies [19]. …”

Section: Peripheral Nervous Systemmentioning

confidence: 99%

“…Repeat testing over time allows for tracking of changes during the course of care [19]. More invasive diagnostic tests that confirm peripheral neuropathy include skin biopsy for the evaluation of intraepidermal nerve fiber density.…”

Section: Diagnosis Of Neuropathymentioning

confidence: 99%

Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy

Kim¹,

Dougherty²,

Abdi³

2015

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity of several chemotherapeutics used in the treatment of all the most common malignancies. There are several defined mechanisms of nerve damage that take place along different areas of the peripheral and the central nervous system. Treatment is based on symptom management and there are several classes of medications found to be efficacious in the treatment of neuropathic pain. Neuropathic pain that persists despite appropriate pharmacotherapy may respond to interventional procedures that span a range of invasiveness. The purpose of this review article is to examine the basic science of neuropathy and currently available treatment options in the context of chemotherapy induced peripheral neuropathy.

show abstract

Brief review: Chemotherapy-induced painful peripheral neuropathy (CIPPN): current status and future directions

Cited by 25 publications

References 79 publications

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

AAPT Diagnostic Criteria for Chronic Cancer Pain Conditions

Involving patients and nurses in choosing between two validated questionnaires to identify chemotherapy‐induced peripheral neuropathy before implementing in clinical practice—A qualitative study

Basic science and clinical management of painful and non-painful chemotherapy-related neuropathy

Contact Info

Product

Resources

About